An unexpected strategy to alleviate hypoxia limitation of photodynamic therapy by biotinylation of photosensitizers

Jing An, Shanliang Tang, Gaobo Hong, Wenlong Chen, Miaomiao Chen, Jitao Song, Zhiliang Li, Xiaojun Peng, Fengling Song () and Wen-Heng Zheng ()
Additional contact information
Jing An: Dalian University of Technology
Shanliang Tang: Dalian University of Technology
Gaobo Hong: Dalian University of Technology
Wenlong Chen: Dalian University of Technology
Miaomiao Chen: Dalian University of Technology
Jitao Song: Shandong University
Zhiliang Li: Shandong University
Xiaojun Peng: Dalian University of Technology
Fengling Song: Dalian University of Technology
Wen-Heng Zheng: Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute

Nature Communications, 2022, vol. 13, issue 1, 1-10

Abstract: Abstract The most common working mechanism of photodynamic therapy is based on high-toxicity singlet oxygen, which is called Type II photodynamic therapy. But it is highly dependent on oxygen consumption. Recently, Type I photodynamic therapy has been found to have better hypoxia tolerance to ease this restriction. However, few strategies are available on the design of Type I photosensitizers. We herein report an unexpected strategy to alleviate the limitation of traditional photodynamic therapy by biotinylation of three photosensitizers (two fluorescein-based photosensitizers and the commercially available Protoporphyrin). The three biotiylated photosensitizers named as compound 1, 2 and 3, exhibit impressive ability in generating both superoxide anion radicals and singlet oxygen. Moreover, compound 1 can be activated upon low-power white light irradiation with stronger ability of anion radicals generation than the other two. The excellent combinational Type I / Type II photodynamic therapy performance has been demonstrated with the photosensitizers 1. This work presents a universal protocol to provide tumor-targeting ability and enhance or trigger the generation of anion radicals by biotinylation of Type II photosensitizers against tumor hypoxia.

Date: 2022
References: View complete reference list from CitEc
Citations: View citations in EconPapers (9)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-29862-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-29862-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-29862-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().